
AXA launches €440 m private equity healthcare strategy
The Strategy focuses specifically on companies in four core areas: medical devices, biopharmaceuticals, vaccines, and diagnostics. The...

Mimetas BV participating in €325m cancer funding
As part of a financing of the Dutch Naional Growth Fund the Oncode-PACT (Preclinical Accelerator for Cancer Treatments) initiative has been granted...

XNK Therapeutics AB raises €12.75m
XNK Therapeutics said it will use the proceeds to accelerate an investigator-initiateed open Phase II study with its autologous NK cell-based...

Affimed prices public offering to finance NK cell trials
German Affimed N.V. has priced its previously announced public offering of 22,500,000 common shares at a $4.00 per common share. A 30-day...

International Vaccine Institute – IVI – will locate its European office in Stockholm
The International Vaccine Institute, IVI, is establishing itself outside South Korea for the first time. Last week, the Swedish Parliament ratified...

Roche obtains special authorisation for bispecific antibody
Roches new developed immunotherapy is based on a bispecific antibody, which targets B-lymphocyte antigen CD20 and the CD3-T-cell receptor at the...

Engimmune Therapeutics raises CHF15.5m in seed financing
Pureos Bioventures and Novo Holdings co-led the financing of Engimmune Therapeutics, a spin-off from the research group of Prof. Sai Reddy at the...